Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Continue to Remain...

    Continue to Remain Opportunistic For Acquisitions: Sun Pharma

    Written by savita thakur thakur Published On 2016-06-09T11:47:44+05:30  |  Updated On 9 Jun 2016 11:47 AM IST

    New Delhi : Keen on inorganic expansion, Sun Pharma has said it is looking for targets that are "well managed" unlike the acquisition of Ranbaxy which continues to take significant time of the senior management.


    "We continue to remain opportunistic for acquisitions. As on, since Ranbaxy continues to take significant time for senior management, we are not looking at buying businesses where we will have to spend a lot of time in managing," Sun Pharma Managing Director Dilip Shanghvi told analysts in a conference call.


    So the company continues to look for opportunities which are well managed and which can either operate as a standalone business or businesses which will not require significant amount of management involvement, he added.


    When asked about the size of the deal the company was looking at for the acquisitions, Shanghvi said: "I think we are a conservative company. So if we understand the business, we would potentially look at larger acquisition. If we do not fully understand the business, then it has to be a reasonably sized acquisition."


    "We would not make a very large acquisition in a business which we do not fully understand," he added.


    Shanghvi said the process of integrating Ranbaxy with Sun Pharma has commenced with a view to ensure business momentum and drive value creation.


    "We continue to target synergy benefits of USD 250 million in the third year post closure," he added.


    The merger between Sun and Ranbaxy achieved closure towards the end of March 2015.


    "The Ranbaxy merger closure has taken more time than originally envisaged. We have recently commenced the implementation of the integration process," Shanghvi said.


    In April, 2014, Sun Pharma had announced it would acquire troubled rival Ranbaxy in an all-stock transaction worth USD 4 billion that includes USD 800 million debt.


    The merger created India's largest and the world's fifth largest drugmaker.

    Dilip ShanghviRanbaxySun Pharma
    Source : PTI

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    savita thakur thakur
    savita thakur thakur
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok